FDA relaxes SCENESSE postmarketing requirement
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Clinuvel Pharmaceuticals Limited announced that the FDA has relaxed postmarketing requirements for SCENESSE, removing the need for a cardiac study after reviewing safety data. The FDA determined that the cardiac repolarization study was unnecessary, reflecting the long-term safety profile of SCENESSE.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallClinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
- Final EMA scientific advice for pivotal Phase III vitiligo
- CLINUVEL's global programs showcased at AAD
- Chair Letter to Shareholders
- Half Year Results Presentation
Later from Clinuvel Pharmaceuticals
- CLINUVEL update on Level II ADR upgrade, Nasdaq uplist
- CLINUVEL publicly files 20-F to U.S. SEC
- SCENESSE approved for EPP in Canada
- CLINUVEL strategic reorganisation to refocus on U.S. markets
- CLINUVEL implements strategic reorganisation to refocus on U.S. markets
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals